Last reviewed · How we verify
Etravirine (ETR)
Etravirine (ETR) is a Non-nucleoside reverse transcriptase inhibitor (NNRTI) Small molecule drug developed by ViiV Healthcare. It is currently FDA-approved for HIV-1 infection in treatment-experienced patients with NNRTI resistance, HIV-1 infection in antiretroviral-experienced adults. Also known as: TMC125, Intelence.
Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds to HIV-1 reverse transcriptase and blocks its ability to convert viral RNA into DNA.
Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds to HIV-1 reverse transcriptase and blocks its ability to convert viral RNA into DNA. Used for HIV-1 infection in treatment-experienced patients with NNRTI resistance, HIV-1 infection in antiretroviral-experienced adults.
At a glance
| Generic name | Etravirine (ETR) |
|---|---|
| Also known as | TMC125, Intelence |
| Sponsor | ViiV Healthcare |
| Drug class | Non-nucleoside reverse transcriptase inhibitor (NNRTI) |
| Target | HIV-1 reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Etravirine inhibits HIV-1 reverse transcriptase through a non-competitive binding mechanism, preventing the enzyme from synthesizing viral DNA from the viral RNA genome. This blocks HIV replication and reduces viral load in infected individuals. It is particularly effective against certain drug-resistant HIV strains due to its unique binding interactions with the reverse transcriptase enzyme.
Approved indications
- HIV-1 infection in treatment-experienced patients with NNRTI resistance
- HIV-1 infection in antiretroviral-experienced adults
Common side effects
- Rash
- Nausea
- Diarrhea
- Headache
- Vomiting
- Abdominal pain
Key clinical trials
- TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR) (PHASE1)
- Switch Strategy From Etravirine (ETR) to Doravirine (DOR) in Virologically-Suppressed HIV-1 Infected Adults With ETR-Resistance (PHASE4)
- Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children (PHASE1, PHASE2)
- Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL (PHASE2)
- Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I (PHASE3)
- Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Etravirine (ETR) CI brief — competitive landscape report
- Etravirine (ETR) updates RSS · CI watch RSS
- ViiV Healthcare portfolio CI
Frequently asked questions about Etravirine (ETR)
What is Etravirine (ETR)?
How does Etravirine (ETR) work?
What is Etravirine (ETR) used for?
Who makes Etravirine (ETR)?
Is Etravirine (ETR) also known as anything else?
What drug class is Etravirine (ETR) in?
What development phase is Etravirine (ETR) in?
What are the side effects of Etravirine (ETR)?
What does Etravirine (ETR) target?
Related
- Drug class: All Non-nucleoside reverse transcriptase inhibitor (NNRTI) drugs
- Target: All drugs targeting HIV-1 reverse transcriptase
- Manufacturer: ViiV Healthcare — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for HIV-1 infection in treatment-experienced patients with NNRTI resistance
- Indication: Drugs for HIV-1 infection in antiretroviral-experienced adults
- Also known as: TMC125, Intelence
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing